Literature DB >> 7449356

Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.

C S Lee, L H Wang, T C Marbury, J Bruni, R J Perchalski.   

Abstract

The effect of the artificial kidney on the removal of carbamazepine was studied in four uremic patients undergoing chronic hemodialysis. Each patient received 500 mg of carbamazepine PO 8 hr prior to hemodialysis. Predialysis and postdialysis blood samples as well as dialysate samples were collected at various time intervals during a 4-hr hemodialysis. Samples were analyzed for carbamazepine content by HPLC. Dialysis clearance calculated from dialysate measurements averaged 53.6 +/- 10.0 mL/min which is double the reported mean plasma clearance of 27.5 mL/min. Since drug clearance by the dialyzer is twice the endogenous plasma clearance, we conclude that carbamazepine is dialyzable. Despite the significant dialysis clearance, a dosage regimen adjustment may not be necessary because of the long elimination half-life of carbamazepine of 35 hr compared to the short length of the usual hemodialysis treatment of 3-5 hr.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7449356     DOI: 10.3109/15563658008989993

Source DB:  PubMed          Journal:  Clin Toxicol        ISSN: 0009-9309            Impact factor:   4.467


  9 in total

1.  Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.

Authors:  Sara N Davison
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-04       Impact factor: 8.237

2.  Resistant hypertension and PRES syndrome induced by carbamazepine in a patient with SLE: A case report and literature review.

Authors:  Mohammad Alsultan; Kassem Basha
Journal:  Ann Med Surg (Lond)       Date:  2022-05-11

3.  Signs and symptoms of carbamazepine overdose.

Authors:  S Schmidt; M Schmitz-Buhl
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

Review 4.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 5.  Carbamazepine overdose. Features of 33 cases.

Authors:  J F Seymour
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 6.  Antiepileptic drugs in the treatment of neuropathic pain.

Authors:  Elon Eisenberg; Yaron River; Ala Shifrin; Norberto Krivoy
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Carbamazepine toxicity and poisoning. Incidence, clinical features and management.

Authors:  L Durelli; U Massazza; R Cavallo
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

8.  Pain management in patients with chronic kidney disease and end-stage kidney disease.

Authors:  Payel J Roy; Melanie Weltman; Laura M Dember; Jane Liebschutz; Manisha Jhamb
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-11       Impact factor: 3.416

Review 9.  Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Marc Ghannoum; Christopher Yates; Tais F Galvao; Kevin M Sowinski; Thi Hai Vân Vo; Andrew Coogan; Sophie Gosselin; Valery Lavergne; Thomas D Nolin; Robert S Hoffman
Journal:  Clin Toxicol (Phila)       Date:  2014-10-30       Impact factor: 4.467

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.